Trial
NCT03791398
BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Brown University
Collaborators
Rhode Island Hospital; Bristol-Myers Squibb; Oncoceutics, Inc.
Condition
Metastatic Colorectal Cancer
Intervention
Dose level 1 ONC201 625mg
Why stopped
Lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-02-17